European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update

2022/10/01 by Börje Ljungberg, Laurence Albiges, Yasmin Abu-Ghanem +15 · 2 citations

paper · doi:10.1016/j.eururo.2022.03.006

Cited by

• CaboPoint: A Phase 2 Study of Second-line Cabozantinib After Checkpoint Inhibitor–based Combination Therapy in Patients with Metastatic Renal Cell Carcinoma
• PV-1: a novel molecular prognostic marker of distant metastases in various solid tumors